Reply to: Assessing the efficiency of Verily’s automated process for production and release of male Wolbachia-infected mosquitoes
|
|
J. E. Crawford, K. C. Hopkins, A. Buchman, T. Zha, P. Howell, E. Kakani, J. R. Ohm, N. Snoad, L. Upson, J. Holeman, P. Massaro, S. L. Dobson, F. S. Mulligan and B. J. White,
Nature Biotechnology,
2022.
We appreciate the comments from Bouyer et al. under their mandate as a United Nations agency program (‘to promote the safe and appropriate use of nuclear techniques and related technologies in food and agriculture’) on our paper1 . The centuries-old fight against mosquito-borne disease has entered a new phase that is both exciting and fast-moving. Many promising technologies and techniques have been developed in the past 2 decades, including mosquito colonies stably infected with Wolbachia2 mosquitoes3,4, a CRISPR–Cas9-based gene drive5 nations of these techniques with older approaches (that is, irradiated Wolbachia releases6,7 , genetically modified sterile and even combi). In a world where more than half of all humans are at risk of contracting mosquito-borne diseases across a range of economic and geographic landscapes, we think that an array of tools will be needed to turn the tide against the massive public health burden of these diseases. More related to this |
